Advances in research based on antibody-cell conjugation

Front Immunol. 2023 Dec 14:14:1310130. doi: 10.3389/fimmu.2023.1310130. eCollection 2023.

Abstract

Antibody-cell conjugation (ACC) technology is a new research direction in medicine and biotechnology in recent years. The concept of ACC was proposed by Hsiao et al. and developed into a viable cell therapy technology, which refers to the cells with specific functions. Such as natural killer cells (NK cells), cytokine induced killer cells (CIK) and other immune cells and monoclonal antibodies through the linker together formed conjugate. ACC directly modifies specific antibodies on the cell surface through a simple and effective chemical coupling method to enable cells to have new functions. ACC has been developed for the treatment of various diseases, including cancers of the blood system and solid tumors. This paper reviews the current ACC construction methods, challenges and future development directions.

Keywords: antibody-cell conjugation; cancer cell therapy; cancer therapy; monoclonal antibody; tumor targeting therapy.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal
  • Cytokine-Induced Killer Cells*
  • Cytotoxicity, Immunologic
  • Humans
  • Killer Cells, Natural
  • Neoplasms*

Substances

  • Antibodies, Monoclonal

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was funded by the National Natural Science Foundation of China [grant number 52003100].